VIVA Biotech Holdings represents a commitment to innovation, collaboration, and excellence in the biotechnology industry. As a leading company, VIVA strives to provide high-quality drug discovery services and help clients achieve their research goals. The company's corporate philosophy revolves around customer-centric solutions, where their experienced team utilizes cutting-edge technologies and state-of-the-art facilities to deliver best-in-class services. With a focus on rapid and cost-effective drug development, VIVA Biotech Holdings aims to contribute extensively to the advancement of healthcare and pharmaceutical breakthroughs.

VIVA Biotech Holdings is primarily present in China and the United States.

VIVA Biotech Holdings has achieved several significant milestones. Firstly, the company successfully listed on the Hong Kong Stock Exchange in 2019, marking an important step in its growth. Additionally, VIVA Biotech has consistently demonstrated its strength in drug discovery services and collaborations. It has established numerous strategic partnerships with leading pharmaceutical companies globally, fueling its reputation as a trusted biotech partner. Moreover, VIVA Biotech has expanded its operations by opening multiple state-of-the-art research centers in China and abroad. These accomplishments highlight VIVA Biotech Holdings' continuous commitment to innovation, partnerships, and global expansion within the biotech industry.

VIVA Biotech Holdings is a leading structure-based drug discovery platform established in 2008. The company primarily focuses on enabling and supporting biotechnology and pharmaceutical companies in their drug discovery and development efforts. VIVA Biotech Holdings has a proven track record of success in assisting clients to identify and optimize potential drug candidates. Through its innovative services and expertise, the company has built a strong reputation and has become a trusted partner in the biotech industry. With a commitment to scientific excellence and cutting-edge technology, VIVA Biotech Holdings continues to contribute to advancements in drug discovery, making valuable contributions to the healthcare sector.

Some of the main competitors of VIVA Biotech Holdings in the market include Charles River Laboratories, Evotec AG, WuXi AppTec, Eurofins Scientific, and Albany Molecular Research Inc.

VIVA Biotech Holdings is primarily active in the biotechnology and pharmaceutical industries.

The business model of VIVA Biotech Holdings focuses on providing comprehensive and high-quality drug discovery services to global pharmaceutical and biotechnology companies. VIVA Biotech offers structure-guided drug discovery (SGDD) and other innovative technologies to accelerate the development of potential therapeutics. By leveraging its advanced platform and expertise, VIVA Biotech aims to identify and optimize drug candidates with high success rates. With a strong emphasis on collaboration and efficient processes, the company strives to facilitate the discovery and development of novel drugs, ultimately contributing to advancements in the healthcare industry.

מכפיל הרווחים למניה של VIVA Biotech Holdings הוא 3.77.

מכפיל המכירות של VIVA Biotech Holdings הוא 0.55.

תוצאת איכות AlleAktien עבור VIVA Biotech Holdings היא 4/10.

המחזור מצופה VIVA Biotech Holdings הוא 3.03 מיליארד CNY.

הרווח של מצופה VIVA Biotech Holdings הוא 439.11 מיליון CNY.

VIVA Biotech Holdings is a leading biopharmaceutical company offering a comprehensive range of top-quality services and advanced research tools. The company provides a wide range of solutions to support research and development projects in the field of biology, particularly in the areas of biochemistry, biotechnology, and drug development. The business model of VIVA Biotech Holdings is based on three main divisions: Viva Biotech, Viva Biotech Hutchison, and VivaBioCell. Viva Biotech is a leading service provider for drug discovery and development. The company offers comprehensive biological research services to accelerate drug development, with a focus on the rapid identification of high-quality drug candidates through the use of cutting-edge technology platforms and instruments. Viva Biotech Hutchison is a strategic partnership between the company and Hutchison China MediTech Limited, a leading Chinese biopharmaceutical company. The partnership includes a unique platform for drug discovery and development, securing access to proprietary technologies and instruments. The collaboration enables VIVA Biotech to offer a comprehensive and competitive value chain in drug development. The third division, VivaBioCell, is a specialized laboratory offering primary and cultured human cells. These cells are used in research to understand bioprocesses and develop innovative approaches to treating serious diseases. VivaBioCell enables the provision of high-quality cells in the shortest possible time, providing a competitive advantage. VIVA Biotech Holdings' portfolio includes a wide range of products and services, ranging from chemical molecule modeling to the manufacture of drug candidates. The offerings also include advanced screening approaches, protein production, structural elucidation, in vitro screening, and in vivo animal testing. Viva Biotech's biological research services utilize state-of-the-art technology platforms such as high-throughput screening, protein structural elucidation, and single-cell technology. The company has a network of over 600 customers, including biotechnology and pharmaceutical companies, as well as research institutions in North America, Europe, and Asia. The versatile and scientifically sound expertise of VIVA Biotech Holdings enables the company to develop tailored solutions for customer projects to achieve optimal results. In addition, VIVA Biotech Holdings has its own portfolio of selected drug candidates with potential for clinical success, which are sought after in the pharmaceutical industry. The portfolio consists of eight drug candidates, including two in Phase III clinical trials. VIVA Biotech Holdings' business model is based on extensive biological expertise, cutting-edge technology platforms, and a wide range of products and services to support biology research and development projects. The company specializes in the accelerated discovery of high-quality drug candidates, providing a competitive advantage over other companies in the market.

VIVA Biotech Holdings מחלקת דיבידנד בסכום של 0 CNY במספר תשלומים במהלך השנה.

לא ניתן לחשב כרגע את הדיבידנד עבור VIVA Biotech Holdings או שהחברה אינה מפרישה דיבידנד.

ISIN של VIVA Biotech Holdings היא KYG9390W1015.

ה-WKN של VIVA Biotech Holdings הוא A2PH5Q.

הטיקר של VIVA Biotech Holdings הוא 1873.HK.

במהלך 12 החודשים האחרונים, VIVA Biotech Holdings שילמה דיבידנד בגובה 0.01 CNY . זה מקביל לתשואת דיבידנד של כ-1.17 %. ל-12 החודשים הקרובים, VIVA Biotech Holdings צפויה לשלם דיבידנד של 0 CNY.

תשואת הדיבידנד של VIVA Biotech Holdings נוכחית היא 1.17 %.

VIVA Biotech Holdings משלמת דיבידנד רבעוני. הדיבידנד מתבצע בחודשים אוקטובר, יולי, אוקטובר, יולי.

VIVA Biotech Holdings שילם דיבידנד כל שנה במשך ה-2 שנים האחרונות.

לתקופה הבאה של 12 חודשים ניתן לצפות לדיבידנדים בסך של 0 CNY. זה מייצג תשואת דיבידנד של 0 %.

VIVA Biotech Holdings משויך למגזר 'בריאות'.

כדי לקבל את הדיבידנד האחרון של VIVA Biotech Holdings מתאריך 9.7.2021 בסך 0.01 CNY, היה עליך להחזיק את המניה לפני היום המוקדם בתאריך 16.6.2021 בתיק.

תשלום הדיבידנד האחרון בוצע ב-9.7.2021.

בשנת 2023 שילמה VIVA Biotech Holdings 0 CNY כדיבידנדים.

הדיבידנדים של VIVA Biotech Holdings מתחלקים ב-CNY.